- Incyte announced that Minjuvi (tafasitamab), in combination with R² (lenalidomide and rituximab), is now funded in Ontario through the Funding Accelerated for Specific Treatments (FAST) Program for eligible patients with relapsed or refractory follicular lymphoma (R/R FL).
- The FAST pathway allows eligible patients to access Minjuvi sooner while formal reimbursement processes continue, expanding treatment options for a chronic blood cancer in which relapse is common.
- FL is the second most common subtype of non-Hodgkin lymphoma. About 20% of patients experience disease progression within 2 years of chemotherapy, while subsequent relapses can lead to shorter remissions and increasing treatment complexity.
- The funding milestone reflects Ontario’s efforts to accelerate access to innovative cancer therapies and provides eligible patients with another targeted treatment option as Incyte continues to work with Canadian healthcare stakeholders.
Takeaways:
Ontario’s FAST Program funding for Minjuvi (tafasitamab) plus R² gives eligible patients with relapsed or refractory follicular lymphoma earlier public access to a targeted anti‑CD19 option while formal reimbursement reviews continue, addressing a setting where relapses are common and treatment choices narrow over time. As the first province to fund Minjuvi in FL, Ontario sets an early reference point that can influence uptake and negotiations in other jurisdictions, strengthening Incyte’s position in the Canadian lymphoma market alongside other targeted and cellular therapies.
Source: CA Newswire
